131 related articles for article (PubMed ID: 38430555)
1. Bifunctional Sildenafil Diazeniumdiolates Acting as Phosphodiesterase 5 Inhibitors and Nitric Oxide Donors- Towards Wound Healing.
Mas-Roselló J; Tenor H; Szabo T; Naef R; Sieber S; Gademann K
Chembiochem; 2024 Apr; 25(8):e202300801. PubMed ID: 38430555
[TBL] [Abstract][Full Text] [Related]
2. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery.
Andersson KE
Br J Pharmacol; 2018 Jul; 175(13):2554-2565. PubMed ID: 29667180
[TBL] [Abstract][Full Text] [Related]
3. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation.
Gudmundsdóttir IJ; McRobbie SJ; Robinson SD; Newby DE; Megson IL
Biochem Biophys Res Commun; 2005 Nov; 337(1):382-5. PubMed ID: 16185664
[TBL] [Abstract][Full Text] [Related]
4. Sildenafil Prevents Apoptosis of Human First-Trimester Trophoblast Cells Exposed to Oxidative Stress: Possible Role for Nitric Oxide Activation of 3',5'-cyclic Guanosine Monophosphate Signaling.
Bolnick JM; Kilburn BA; Bolnick AD; Diamond MP; Singh M; Hertz M; Dai J; Armant DR
Reprod Sci; 2015 Jun; 22(6):718-24. PubMed ID: 25431453
[TBL] [Abstract][Full Text] [Related]
5. A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide.
Kalsi JS; Ralph DJ; Thomas P; Bellringer J; Minhas S; Kell PD; Cellek S
J Sex Med; 2005 Jan; 2(1):53-7. PubMed ID: 16422907
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 5 inhibition ameliorates angiotensin II-dependent hypertension and renal vascular dysfunction.
Thieme M; Sivritas SH; Mergia E; Potthoff SA; Yang G; Hering L; Grave K; Hoch H; Rump LC; Stegbauer J
Am J Physiol Renal Physiol; 2017 Mar; 312(3):F474-F481. PubMed ID: 28052870
[TBL] [Abstract][Full Text] [Related]
7. Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.
Peuler JD; Phelps LE
J Smooth Muscle Res; 2015; 51():22-36. PubMed ID: 26004378
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 5 (PDE5) inhibition, ANP and NO rapidly reduce epididymal duct contractions, but long-term PDE5 inhibition in vivo does not.
Mietens A; Tasch S; Feuerstacke C; Eichner G; Volkmann J; Schermuly RT; Grimminger F; Müller D; Middendorff R
Mol Cell Endocrinol; 2012 Feb; 349(2):145-53. PubMed ID: 21996373
[TBL] [Abstract][Full Text] [Related]
9. NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide.
Kalsi JS; Kell PD; Cellek S; Ralph DJ
Int J Impot Res; 2004 Apr; 16(2):195-200. PubMed ID: 14961060
[TBL] [Abstract][Full Text] [Related]
10. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
[TBL] [Abstract][Full Text] [Related]
11. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
[TBL] [Abstract][Full Text] [Related]
12. Protection of sildenafil citrate hydrogel against radiation-induced skin wounds.
Kulshrestha S; Chawla R; Singh S; Yadav P; Sharma N; Goel R; Ojha H; Kumar V; Adhikari JS
Burns; 2020 Aug; 46(5):1157-1169. PubMed ID: 31870570
[TBL] [Abstract][Full Text] [Related]
13. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
[TBL] [Abstract][Full Text] [Related]
14. Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions.
Biswas KH; Visweswariah SS
J Biol Chem; 2011 Mar; 286(10):8545-8554. PubMed ID: 21193396
[TBL] [Abstract][Full Text] [Related]
15. Sildenafil reduces aortic endothelial dysfunction and structural damage in spontaneously hypertensive rats: Role of NO, NADPH and COX-1 pathways.
Leal MAS; Aires R; Pandolfi T; Marques VB; Campagnaro BP; Pereira TMC; Meyrelles SS; Campos-Toimil M; Vasquez EC
Vascul Pharmacol; 2020 Jan; 124():106601. PubMed ID: 31689530
[TBL] [Abstract][Full Text] [Related]
16. Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction.
González-Corrochano R; La Fuente J; Cuevas P; Fernández A; Chen M; Sáenz de Tejada I; Angulo J
Br J Pharmacol; 2013 May; 169(2):449-61. PubMed ID: 23441682
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
Corbin JD; Francis SH; Webb DJ
Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
[TBL] [Abstract][Full Text] [Related]
18. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
Dunkern TR; Hatzelmann A
Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Multifaceted Potential of Sildenafil in Medicine.
Pușcașu C; Zanfirescu A; Negreș S; Șeremet OC
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138293
[TBL] [Abstract][Full Text] [Related]
20. Induction of PDE5 and de-sensitization to endogenous NO signaling in a systemic resistance artery under altered blood flow.
Zhang H; Pakeerappa P; Lee HJ; Fisher SA
J Mol Cell Cardiol; 2009 Jul; 47(1):57-65. PubMed ID: 19374906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
